BRBR vs. ITCI, VKTX, MASI, INSP, CERE, GMED, JAZZ, EXEL, CYTK, and HQY
Should you be buying BellRing Brands stock or one of its competitors? The main competitors of BellRing Brands include Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Masimo (MASI), Inspire Medical Systems (INSP), Cerevel Therapeutics (CERE), Globus Medical (GMED), Jazz Pharmaceuticals (JAZZ), Exelixis (EXEL), Cytokinetics (CYTK), and HealthEquity (HQY). These companies are all part of the "medical" sector.
BellRing Brands (NYSE:BRBR) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
BellRing Brands has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.
Intra-Cellular Therapies received 394 more outperform votes than BellRing Brands when rated by MarketBeat users. Likewise, 67.34% of users gave Intra-Cellular Therapies an outperform vote while only 66.46% of users gave BellRing Brands an outperform vote.
BellRing Brands has higher revenue and earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than BellRing Brands, indicating that it is currently the more affordable of the two stocks.
BellRing Brands currently has a consensus target price of $57.62, indicating a potential upside of 3.48%. Intra-Cellular Therapies has a consensus target price of $90.17, indicating a potential upside of 25.01%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Intra-Cellular Therapies is more favorable than BellRing Brands.
In the previous week, Intra-Cellular Therapies had 15 more articles in the media than BellRing Brands. MarketBeat recorded 22 mentions for Intra-Cellular Therapies and 7 mentions for BellRing Brands. BellRing Brands' average media sentiment score of 0.78 beat Intra-Cellular Therapies' score of 0.57 indicating that BellRing Brands is being referred to more favorably in the media.
95.0% of BellRing Brands shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 0.8% of BellRing Brands shares are held by company insiders. Comparatively, 3.4% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BellRing Brands has a net margin of 9.52% compared to Intra-Cellular Therapies' net margin of -30.08%. Intra-Cellular Therapies' return on equity of -23.02% beat BellRing Brands' return on equity.
Summary
Intra-Cellular Therapies beats BellRing Brands on 9 of the 17 factors compared between the two stocks.
Get BellRing Brands News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRBR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BellRing Brands Competitors List
Related Companies and Tools
